Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement ...

Novo Nordisk (NVO) stock is in focus after signing a $1.4B deal with Orbis Medicines to develop oral drugs for ...

Novo Nordisk A/S agreed to work with Orbis Medicines ApS on next-generation pills for heart and metabolic diseases in a ...

Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion ...

Novo Nordisk (OVO) teams up with Orbis Medicine to develop oral cardiometabolic treatments—in a deal worth up to $1.4B. Read ...

Novo Nordisk (NVO) signed a strategic collaboration and license agreement with Orbis Medicines to develop oral macrocycle therapeutics for cardiometabolic diseases, Orbis said Thu ...

Novo Nordisk stock ended September 18, 2026 at USD 43.23, and the intraday range on MarketBeat stretched from USD 42.78 to ...

Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 biobucks pact with ...

Investing.com -- Orbis Medicines周四宣布与诺和诺德公司（ CSE:NOVOb ）签署一项药物研发及授权协议，该协议潜在总价值高达14亿美元，旨在将目前需要注射给药的心脏代谢疾病治疗药物开发为口服制剂。

丹麥藥廠諾和諾德(NVO.US)與Orbis Medicines達成一項最高價值14億美元的授權協議，由這間私人公司開發針對心血管代謝疾病的口服藥物。 Orbis周四表示，該公司可獲得最高14億美元的預付款及里程碑付款，另加未來產品銷售的特許權使用費。諾和諾德亦將對Orbis作出「策略性投資」。 諾和諾德於紐約證券交易所上市的股份最新升2.2%，今年以來跌幅收窄至16%。 兩家公司旨在加快開發新一 ...

Danish drugmaker Novo Nordisk has entered into a strategic collaboration and licensing agreement with domestic peer Orbis Medicines to develop next-generation oral therapies for cardiometabolic ...

Novo Nordisk signs a deal worth up to $1.4bn with Orbis Medicines to develop oral drugs for cardiometabolic diseases.